Top Markets
#1 0G 0G +45.73%
#2 Merlin's Seal BTC Merlin's Seal BTC +42.87%
#3 Useless Coin Useless Coin +30.72%
#4 SAFEcoin SAFEcoin +28.84%
#5 Dogs Dogs +24.05%
#6 Pons Pons +24.05%
#7 StonkBroker StonkBroker +21.73%
#8 ICON ICON +20.45%
#9 Zora Zora +20.32%
#10 Dash Dash +17.58%
Coin of the day
0G 0G
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Graphite Bio, Inc. Graphite Bio, Inc.

Graphite Bio, Inc.

GRPH
Clasificación en acciones #12750
Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to... Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to developing innovative therapeutic solutions for severe and life-threatening illnesses across the United States. Its primary investigational therapy, GPH101, is an autologous, gene-edited hematopoietic stem cell product specifically engineered to directly correct the underlying mutation causing sickle cell disease, thereby restoring normal adult hemoglobin production. The company's pipeline also features GPH201, intended for the treatment of X-linked severe combined immunodeficiency syndrome, and GPH301, an experimental candidate designed to address Gaucher disease, a genetic disorder characterized by a deficiency in the glucocerebrosidase enzyme. Initially established as Integral Medicines, Inc., the company rebranded to Graphite Bio, Inc. in August 2020. Founded in 2017, Graphite Bio's operations are based out of its headquarters in South San Francisco, California.
Precio por acción
$22.26
Última sincronización: 2024-03-22
Capitalización bursátil
$553.40M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Graphite Bio, Inc. (GRPH)

Categoría

Healthcare
Ingresos de Graphite Bio, Inc. (GRPH)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de Graphite Bio, Inc., los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Graphite Bio, Inc. desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH